ULGX Projected Dividend Yield

Urologix Inc. ( OTCBB : ULGX )

Urologix develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from non-cancerous prostate enlargement also known as benign prostatic hyperplasia (BPH). Co.'s Cooled ThermoTherapy? uses a flexible catheter to deliver microwave energy combined with a cooling mechanism to provide relief from BPH voiding symptoms by the thermal ablation of hyperplastic prostatic tissue surrounding the urethra. Co.'s Prostiva® Radio Frequency Therapy System delivers radio frequency energy directly into the prostate using insulated electrodes, ablating targeted prostatic tissue under the direct visualization of the urologist.

20 YEAR PERFORMANCE RESULTS